TreverGBivonaMD
Oncology • San Francisco, CAAssistant Professor, Medicine, University of California, San Francisco, School of Medicine
Dr. Bivona is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1600 Divisadero Street 4th floor
Box 1674
San Francisco, CA 94115Phone+1 415-353-7160
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2011
Brigham and Women's HospitalResidency, Internal Medicine, 2005 - 2007
New York University School of MedicineClass of 2005
Certifications & Licensure
CA State Medical License 2012 - 2025
NY State Medical License 2007 - 2012
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Publications & Presentations
PubMed
- Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping...Matthew S Lara, Jonathan W Riess, Jonathan W Goldman, Fei Jiang, Trever G Bivona
Clinical Lung Cancer. 2024-12-01 - 2 citationsFET fusion oncoproteins disrupt physiologic DNA repair networks in cancer.Shruti Menon, Daniel Gracilla, Marcus R Breese, Yone Phar Lin, Filemon Dela Cruz
Biorxiv. 2024-11-21 - Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance.David Gonzalez-Martinez, Lee Roth, Thomas R Mumford, Juan Guan, Anh Le
Nature Communications. 2024-11-02
Journal Articles
- Aurora Kinase A Drives the Evolution of Resistance to Third-Generation EGFR Inhibitors in Lung CancerVictoria E Wang, Collin M Blakely, Trever G Bivona, Andrei Goga, Nature
- Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient with a MET Exon 14 Skipping MutationJulia K Rotow, Trever G Bivona, Collin M Blakely, Clinical Lung Cancer
- RAS Nucleotide Cycling Underlies the SHP2 Phosphatase Dependence of Mutant BRAF-, NF1- and RAS-Driven CancersTrever Bivona, MD, Nature
Authored Content
- Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient with a MET Exon 14 Skipping MutationNovember 2018
Press Mentions
Damon Runyon Cancer Research Foundation Awards over $4.1 Million to Exceptional Early-Career ScientistsJuly 28th, 2022- Damon Runyon Cancer Research Foundation Awards $4.8 Million to Rising InvestigatorsJuly 15th, 2021
- Novel Structure Found in Tumor Cells May Open Door to New Kinds of Cancer TherapiesMay 11th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
